By contrast, Zenlander et al., in a clinical study on 227 patients with cirrhosis, HCC, and controls, found that CitH3 and MPO-DNA were significantly elevated in patients with end-stage liver cirrhosis and HCC as compared with controls. This evidence concerns the gene MPO and hepatocellular carcinoma.